A Phase 2 interventional study of Vedolizumab in Ulcerative Colitis and Crohn's Disease, sponsored by Takeda. Completed at 23 sites in 7 countries. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-05-13.
Sponsored by Takeda · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies testing vedolizumab in Colitis, Ulcerative — 5 open to participants now, 9 under way, 6 of them phase 3. vedolizumab · Colitis, Ulcerative.
Among the 38 studies testing vedolizumab in Colitis, Ulcerative, this one is the 27th largest by enrollment, is one of 2 that started in 2018, is one of 5 in phase 2, and was the 18th registered.
1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.
Browse Colitis, Ulcerative studies →5 of the 38 studies testing vedolizumab in Colitis, Ulcerative are open now, in 12 countries. Recruiting first, the newest first:
Takeda · Sites in United States, Belgium, Bulgaria and 11 more countries
Ages 2–17
Takeda · Sites in United States
Ages 18–80
Takeda · Sites in United States, Belgium, Bulgaria and 13 more countries
Ages 2–17
Takeda · Sites in United States, Australia, Belgium and 15 more countries
Ages 2+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
vedolizumab: first FDA approval 2014 (ENTYVIO), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.
This study: 2 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 2 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 59 is below the median of 70 across 1,237 interventional studies indexed under Colitis, Ulcerative.
Median enrollment 110 across the 38 interventional studies. Of the 23 that completed or were terminated, 16 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 38 have an industry lead sponsor. The 10 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
68 studies in Colitis, Ulcerative by Takeda: 6 open now, 10 under way, 5 of them phase 3. Of 54 finished, 35 (65%) have results posted.
Among the 68 studies in Colitis, Ulcerative by Takeda, this one is the 34th largest by enrollment of the 43 interventional ones that give a count, is one of 8 that started in 2018, is one of 10 in phase 2, and was the 31st registered.
Takeda’s Colitis, Ulcerative studies by the year they started, since 2003.
4 of the studies testing vedolizumab in Colitis, Ulcerative that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06880744Phase 3AbbVieA Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab | 2027-08 |
| NCT03221036Phase 3TakedaEfficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis | 2027-09-24 |
| NCT06581328TakedaA Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting | 2027-05-01 |
| NCT06095128TakedaA Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC) | 2027-07-09 |
Add all 4 to your calendar (.ics) → With an account.
Among the 38 studies testing vedolizumab in Colitis, Ulcerative, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 68 in Colitis, Ulcerative:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the safety profile of long-term vedolizumab IV treatment in pediatric participants with UC or CD.
The drug being tested in this study is called Vedolizumab. Vedolizumab is being tested to treat pediatric participants who have moderately to severely active UC or CD.
This study will look at the long-term safety profile in participants who take vedolizumab IV. Participants will continue receiving the same dose assigned from the parent study MLN0002-2003 [NCT03138655], which will remain blinded until week 40.
The dosing regimen selected for the long-term study is intended to maintain clinical response at the lowest possible exposure.
At the discretion of the investigator, participants receiving the low dose (150 or 100 milligram [mg]) of vedolizumab IV may be escalated to the high dose (300 or 200 mg) if the participants demonstrate disease worsening at 2 consecutive visits (scheduled or unscheduled).
Participants who experience continued disease worsening during the study despite being administered vedolizumab 300 or 200 mg every 8 weeks (Q8W) will be discontinued from the study.
Study duration will be until vedolizumab IV is commercially available for pediatric indication(s) in the participant's country or until other drug access programs become available (whichever comes first), the participant turns 18 years of age and can be transitioned to commercial drug, the participant withdraws from the study, or the sponsor decides to close the study (up to approximately 8 years).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Is male or female with UC or CD and was between 2 to 17 years, inclusive, at the time of randomization for Study MLN0002-2003.
(Note: A participant remains eligible to participate in this study after they reach 18 years of age if they continue to meet the inclusion criteria and do not meet any exclusion criteria.)
May be receiving a therapeutic dose of the following drugs:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with UC or CD having baseline weight of greater than or equal to (\>=) 30 kilogram (kg) will receive vedolizumab 300 mg and participants with UC or CD having baseline weight of less than (\<) 30 kg will receive vedolizumab 200 mg, IV infusion, every 8 weeks until vedolizumab IV is commercially available for pediatric indication(s) in the participant's country or until other drug access programs become available (whichever comes first), the participant turns 18 years of age and can be transitioned to commercial drug (up to approximately 8 years).
Drug: Vedolizumab
Participants with UC or CD having baseline weight of \>= 30 kg will receive vedolizumab 150 mg and participants with UC or CD having baseline weight of \< 30 kg will receive vedolizumab 100 mg IV infusion, every 8 weeks until vedolizumab IV is commercially available for pediatric indication(s) in the participant's country or until other drug access programs become available (whichever comes first), the participant turns 18 years of age and can be transitioned to commercial drug (up to approximately 8 years).
Drug: Vedolizumab
Vedolizumab intravenous infusion
Also known as: MLN0002, ENTYVIO, KYNTELES
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)
AE defined as any untoward medical occurrence in clinical investigation participants administered drug; it does not necessarily have to have causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (example, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug whether or not it was considered related to the drug. TEAE was defined as an AE whose date of onset occurred on or after the first dose of study drug, or an already-present AE that worsened in intensity or frequency following the treatment start, occurring from the first dose of study drug to the day of last dose of study drug.
Time frame: From first dose of study drug up to end of follow up (up to 6.8 years)
Percentage of Participants With UC Who Achieved and Maintained Clinical Response Based on Complete Mayo Score
Clinical response was defined as a continued reduction in complete Mayo score of \>=3 points and \>=30 percent (%) from baseline (at initiation of MLN0002-2003) and continued decrease in rectal bleeding subscore of \>=1 point from baseline, or absolute rectal bleeding subscore of less than or equal to (\<=1) point. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings on endoscopy and physician rating of disease activity, each graded from 0 to 3 where 0 indicated normal and 3 indicated more severe disease. These scores were summed to give a total score range of 0 to 12; where higher scores indicated more severe disease.
Time frame: At Week 32
Percentage of Participants With CD Who Achieved and Maintained Clinical Response Based on Simple Endoscopic Score for Crohn's Disease (SES-CD) Score and Crohn's Disease Activity Index (CDAI) at Week 32
Maintenance of clinical response based on SES-CD and CDAI was defined as a 50% reduction in SES-CD score on endoscopy compared to the baseline endoscopy \[at initiation of MLN0002-2003 (NCT03138655)\]; and continued reduction in CDAI that is a \>= 70 point decrease from the baseline CDAI score at the initiation of MLN0002-2003 (NCT03138655). CDAI was a research tool used to quantify the symptoms of participants with Crohn's disease. SES-CD consisted of 3 variables: ulcer size, ulcerated and affected surfaces and presence of narrowing each graded from 0 to 3 with score of 0 means no colonic lesions or mucosal healing, and SES-CD greater than (\>) 1 indicated the presence of mucosal lesions.
Time frame: At Week 32
Time to Major Inflammatory Bowel Disease (IBD) - Related Events
Time to major IBD-related events was defined as time from study treatment start to first major IBD-related hospitalization, surgery, or procedure due to UC and CD.
Time frame: Up to 6.8 years
Change From Baseline in IMPACT-III - Total Score
The IMPACT-III questionnaire was a self-reported measure with 35 closed questions encompassing 6 domains: Bowel Symptoms (7 items), Systemic Symptoms (3 items), Social Functioning (12 items), Body Image (3 items), Treatment/Interventions (3 items), and Emotional Functioning (7 items). The IMPACT-III used a 5-point Likert scale ranging from 1 to 5 for all answers. The total score was obtained by summing individual domain scores. The total score ranged from 35 to 175, with higher scores suggesting better quality of life.
Time frame: Baseline, Weeks 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, and 312
Change From Baseline in IMPACT-III - Bowel Symptoms Domain Score
The IMPACT-III questionnaire was a self-reported measure with 35 closed questions encompassing 6 domains. The Bowel Symptoms domain consisted of 7 items. Each item was scored using a 5-point Likert scale ranging from 1 to 5. The bowel symptoms domain score ranged from 7 to 35, with higher scores suggesting a better quality of life.
Time frame: Baseline, Weeks 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, and 312
Change From Baseline in IMPACT-III - Systemic Symptoms Domain Score
The IMPACT-III questionnaire was a self-reported measure with 35 closed questions encompassing 6 domains. The systemic symptoms domain consisted of 3 items. Each item was scored using a 5-point Likert scale ranging from 1 to 5. The systemic symptoms domain score ranged from 3 to 15, with higher scores suggesting a better quality of life.
Time frame: Baseline, Weeks 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, and 312
Change From Baseline in IMPACT-III - Social Functioning Domain Score
The IMPACT-III questionnaire was a self-reported measure with 35 closed questions encompassing 6 domains. The social functioning domain consisted of 12 items. Each item was scored using a 5-point Likert scale ranging from 1 to 5. The social functioning domain score ranged from 12 to 60, with higher scores suggesting a better quality of life.
Time frame: Baseline, Weeks 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, and 312
Change From Baseline in IMPACT-III - Body Image Domain Score
The IMPACT-III questionnaire was a self-reported measure with 35 closed questions encompassing 6 domains. The body image domain consisted of 3 items. Each item was scored using a 5-point Likert scale ranging from 1 to 5. The body image domain score ranged from 3 to 15, with higher scores suggesting a better quality of life.
Time frame: Baseline, Weeks 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, and 312
Change From Baseline in IMPACT-III - Treatment/Interventions Domain Score
The IMPACT-III questionnaire was a self-reported measure with 35 closed questions encompassing 6 domains. The treatment/interventions domain consisted of 3 items. Each item was scored using a 5-point Likert scale ranging from 1 to 5. The treatment/interventions domain score ranged from 3 to 15, with higher scores suggesting a better quality of life.
Time frame: Baseline, Weeks 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, and 312
Change From Baseline in IMPACT-III - Emotional Functioning Domain Score
The IMPACT-III questionnaire was a self-reported measure with 35 closed questions encompassing 6 domains. The emotional functioning domain consisted of 7 items. Each item was scored using a 5-point Likert scale ranging from 1 to 5. The emotional functioning domain score ranged from 7 to 35, with higher scores suggesting a better quality of life.
Time frame: Baseline, Weeks 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, and 312
Height Velocity at Week 48 and Every 48 Weeks
Height velocity (centimeter per year \[cm/year\]) was calculated as the change in height divided by the duration \[time between the two height measures\].
Time frame: At Weeks 48, 96, 144, 192, 240, 288, and 336
Change From Baseline in Height
Change from baseline in height was reported.
Time frame: Baseline, Weeks 48, 96, 144, 192, 240, 288, 336
Change From Baseline in Weight
Change from baseline in weight was reported.
Time frame: Baseline, Weeks 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, and 336
Change From Baseline in Body Mass Index (BMI)
BMI was calculated as Weight (in kilograms)/height (in meters square).
Time frame: Baseline, Weeks 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, and 336
Percentage of Participants Who Achieved Tanner Stage V at or Before Age 16 (in Females) or Age 17 (in Males)
Tanner Stage Evaluation was a scale used to evaluate growth parameters standardized for age, sex, and pubertal development. Female pubertal development staged by pubic hair development and breast size; male pubertal development staged by size of the genitalia and development of pubic hair. Rated in 5 stages: stage 1 (no development) to 5 (adult-like development in quantity and size). Tanner stage was assessed at or before age 16 years for females or 17 years for males.
Time frame: Up to 6.8 years
A total of 59 participants with ulcerative colitis (UC) or Crohn's disease (CD) took part in the study across 34 investigative sites in Belgium, United States, France, Hungary, Israel, Poland, Ukraine, and United Kingdom from 30 July 2018 to 17 July 2025.
| Milestone | UC Participants (< 30 kg): Vedolizumab 100 mg | UC Participants (< 30 kg): Vedolizumab 200 mg | CD Participants (< 30 kg): Vedolizumab 100 mg | CD Participants (< 30 kg): Vedolizumab 200 mg | UC Participants (>=30 kg): Vedolizumab 150 mg | UC Participants (>=30 kg): Vedolizumab 300 mg | CD Participants (>=30 kg): Vedolizumab 150 mg | CD Participants (>=30 kg): Vedolizumab 300 mg |
|---|---|---|---|---|---|---|---|---|
| Started | 5 | 9 | 7 | 7 | 10 | 7 | 4 | 10 |
| Uc participants: dose escalated to vedolizumab 300 mg | 2 | 2 | 0 | 0 | 8 | 0 | 0 | 0 |
| Cd participants: dose escalated to vedolizumab 300 mg | 0 | 0 | 2 | 2 | 0 | 0 | 2 | 0 |
| Safety analysis set | 3 | 6 | 5 | 5 | 2 | 7 | 2 | 10 |
| Completed | 2 | 4 | 5 | 2 | 6 | 2 | 1 | 3 |
| Not completed | 3 | 5 | 2 | 5 | 4 | 5 | 3 | 7 |
| Withdrew: Adverse event | 2 | 3 | 0 | 3 | 3 | 3 | 0 | 2 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 2 | 1 | 1 | 0 | 2 | 2 |
| Withdrew: Other | 0 | 1 | 0 | 1 | 0 | 2 | 1 | 2 |
AE defined as any untoward medical occurrence in clinical investigation participants administered drug; it does not necessarily have to have causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (example, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug whether or not it was considered related to the drug. TEAE was defined as an AE whose date of onset occurred on or after the first dose of study drug, or an already-present AE that worsened in intensity or frequency following the treatment start, occurring from the first dose of study drug to the day of last dose of study drug.
| percentage of participants | UC Participants (< 30 kg): Vedolizumab 100 mg | UC Participants (< 30 kg): Vedolizumab 200 mg | CD Participants (< 30 kg): Vedolizumab 100 mg | CD Participants (< 30 kg): Vedolizumab 200 mg | UC Participants (>=30 kg): Vedolizumab 150 mg | UC Participants (>=30 kg): Vedolizumab 300 mg | CD Participants (>=30 kg): Vedolizumab 150 mg | CD Participants (>=30 kg): Vedolizumab 300 mg | UC Participants: Dose Escalated to Vedolizumab 300 mg | CD Participants: Dose Escalated to Vedolizumab 300 mg |
|---|---|---|---|---|---|---|---|---|---|---|
| Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) | 100 | 83.3 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
Clinical response was defined as a continued reduction in complete Mayo score of \>=3 points and \>=30 percent (%) from baseline (at initiation of MLN0002-2003) and continued decrease in rectal bleeding subscore of \>=1 point from baseline, or absolute rectal bleeding subscore of less than or equal to (\<=1) point. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings on endoscopy and physician rating of disease activity, each graded from 0 to 3 where 0 indicated normal and 3 indicated more severe disease. These scores were summed to give a total score range of 0 to 12; where higher scores indicated more severe disease.
| percentage of participants | UC Participants (< 30 kg): Vedolizumab 100 mg | UC Participants (< 30 kg): Vedolizumab 200 mg | UC Participants (>=30 kg): Vedolizumab 150 mg | UC Participants (>=30 kg): Vedolizumab 300 mg |
|---|---|---|---|---|
| Percentage of Participants With UC Who Achieved and Maintained Clinical Response Based on Complete Mayo Score | 50.0 (0.094 to 0.992) | 75.0 (0.541 to —) | 100 | 50 |
Maintenance of clinical response based on SES-CD and CDAI was defined as a 50% reduction in SES-CD score on endoscopy compared to the baseline endoscopy \[at initiation of MLN0002-2003 (NCT03138655)\]; and continued reduction in CDAI that is a \>= 70 point decrease from the baseline CDAI score at the initiation of MLN0002-2003 (NCT03138655). CDAI was a research tool used to quantify the symptoms of participants with Crohn's disease. SES-CD consisted of 3 variables: ulcer size, ulcerated and affected surfaces and presence of narrowing each graded from 0 to 3 with score of 0 means no colonic lesions or mucosal healing, and SES-CD greater than (\>) 1 indicated the presence of mucosal lesions.
| percentage of participants | CD Participants (< 30 kg): Vedolizumab 100 mg | CD Participants (< 30 kg): Vedolizumab 200 mg | CD Participants (>=30 kg): Vedolizumab 150 mg | CD Participants (>=30 kg): Vedolizumab 300 mg |
|---|---|---|---|---|
| Percentage of Participants With CD Who Achieved and Maintained Clinical Response Based on Simple Endoscopic Score for Crohn's Disease (SES-CD) Score and Crohn's Disease Activity Index (CDAI) at Week 32 | 83.3 | 28.6 | 0 | 50.0 |
Time to major IBD-related events was defined as time from study treatment start to first major IBD-related hospitalization, surgery, or procedure due to UC and CD.
| days | UC Participants (< 30 kg): Vedolizumab 100 mg | UC Participants (< 30 kg): Vedolizumab 200 mg | CD Participants (< 30 kg): Vedolizumab 100 mg | CD Participants (< 30 kg): Vedolizumab 200 mg | UC Participants (>=30 kg): Vedolizumab 150 mg | UC Participants (>=30 kg): Vedolizumab 300 mg | CD Participants (>=30 kg): Vedolizumab 150 mg | CD Participants (>=30 kg): Vedolizumab 300 mg | UC Participants: Dose Escalated to Vedolizumab 300 mg | CD Participants: Dose Escalated to Vedolizumab 300 mg |
|---|---|---|---|---|---|---|---|---|---|---|
| Time to Major Inflammatory Bowel Disease (IBD) - Related Events | NA (482.00 to NA) | NA (NA to NA) | NA (NA to NA) | NA (78.00 to NA) | NA (NA to NA) | 2058.00 (32.00 to NA) | NA (NA to NA) | NA (49.00 to NA) | NA (794.00 to NA) | NA (NA to NA) |
The IMPACT-III questionnaire was a self-reported measure with 35 closed questions encompassing 6 domains: Bowel Symptoms (7 items), Systemic Symptoms (3 items), Social Functioning (12 items), Body Image (3 items), Treatment/Interventions (3 items), and Emotional Functioning (7 items). The IMPACT-III used a 5-point Likert scale ranging from 1 to 5 for all answers. The total score was obtained by summing individual domain scores. The total score ranged from 35 to 175, with higher scores suggesting better quality of life.
| score on a scale | UC Participants (< 30 kg): Vedolizumab 100 mg | UC Participants (< 30 kg): Vedolizumab 200 mg | CD Participants (< 30 kg): Vedolizumab 100 mg | CD Participants (< 30 kg): Vedolizumab 200 mg | UC Participants (>=30 kg): Vedolizumab 150 mg | UC Participants (>=30 kg): Vedolizumab 300 mg | CD Participants (>=30 kg): Vedolizumab 150 mg | CD Participants (>=30 kg): Vedolizumab 300 mg | UC Participants: Dose Escalated to Vedolizumab 300 mg | CD Participants: Dose Escalated to Vedolizumab 300 mg |
|---|---|---|---|---|---|---|---|---|---|---|
| Change at Week 24 | — | 1.0 ± 0.00 | 13.0 ± 7.07 | 10.0 ± NA | 9.0 ± 18.38 | -4.3 ± 6.97 | 8.0 ± NA | 2.7 ± 10.39 | -2.9 ± 7.42 | -6.3 ± 2.08 |
| Change at Week 48 | — | 6.0 ± NA | 8.0 ± NA | 19.0 ± NA | 2.5 ± 7.78 | -6.0 ± 10.73 | 16.0 ± NA | 11.0 ± 19.96 | -1.2 ± 9.50 | -1.3 ± 3.79 |
| Change at Week 72 | — | -5.0 ± NA | 11.0 ± NA | 12.0 ± NA | 10.5 ± 16.26 | -1.2 ± 5.02 | 17.0 ± NA | 19.7 ± 24.54 | -0.4 ± 5.83 | 4.0 ± 9.17 |
| Change at Week 96 | — | 2.0 ± NA | 18.0 ± NA | 8.0 ± NA | 13.0 ± 16.97 | -3.4 ± 13.58 | 22.0 ± NA | 17.3 ± 37.87 | 2.1 ± 9.12 | -1.5 ± 10.61 |
| Change at Week 120 | — | -8.0 ± NA | 24.0 ± NA | 32.0 ± NA | 11.0 ± 5.66 | 1.6 ± 7.02 | 8.0 ± NA | -2.7 ± 3.79 | -7.3 ± 10.75 | -3.5 ± 12.02 |
| Change at Week 144 | — | -4.0 ± NA | 31.0 ± NA | -10.0 ± NA | 14.0 ± 14.14 | 1.8 ± 14.17 | -6.0 ± NA | 0.7 ± 10.02 | -6.0 ± 6.63 | -1.0 ± 0.00 |
| Change at Week 168 | — | 1.0 ± NA | 21.0 ± NA | 42.0 ± NA | 7.5 ± 12.02 | 0.3 ± 14.41 | -6.0 ± NA | 8.7 ± 13.32 | -4.3 ± 12.56 | -3.0 ± 4.24 |
| Change at Week 192 | — | -8.0 ± NA | — | 29.0 ± NA | 21.0 ± NA | 4.8 ± 16.64 | 7.0 ± NA | 8.3 ± 7.02 | -5.8 ± 13.26 | -12.5 ± 19.09 |
| Change at Week 216 | — | -5.0 ± NA | — | 21.0 ± NA | 14.5 ± 13.44 | 3.8 ± 15.00 | 4.0 ± NA | 2.00 ± 0.00 | -5.7 ± 18.10 | -0.5 ± 6.36 |
| Change at Week 240 | — | -1.0 ± NA | — | — | 12.5 ± 16.26 | 5.0 ± 9.90 | 15.0 ± NA | 0.0 ± 5.66 | -5.8 ± 18.06 | -4.5 ± 10.61 |
| Change at Week 264 | — | -3.0 ± NA | — | — | 9.5 ± 10.61 | 8.5 ± 20.51 | — | 9.00 ± NA | 2.0 ± 12.77 | 1.0 ± 8.49 |
| Change at Week 288 | — | — | — | — | -2.0 ± NA | 17.0 ± 8.49 | — | 5.0 ± NA | 6.5 ± 13.44 | 3.0 ± NA |
| Change at Week 312 | — | — | — | — | 2.0 ± NA | -7.0 ± NA | — | 12.0 ± NA | 4.5 ± 9.19 | 1.0 ± NA |
The IMPACT-III questionnaire was a self-reported measure with 35 closed questions encompassing 6 domains. The Bowel Symptoms domain consisted of 7 items. Each item was scored using a 5-point Likert scale ranging from 1 to 5. The bowel symptoms domain score ranged from 7 to 35, with higher scores suggesting a better quality of life.
| score on a scale | UC Participants (< 30 kg): Vedolizumab 100 mg | UC Participants (< 30 kg): Vedolizumab 200 mg | CD Participants (< 30 kg): Vedolizumab 100 mg | CD Participants (< 30 kg): Vedolizumab 200 mg | UC Participants (>=30 kg): Vedolizumab 150 mg | UC Participants (>=30 kg): Vedolizumab 300 mg | CD Participants (>=30 kg): Vedolizumab 150 mg | CD Participants (>=30 kg): Vedolizumab 300 mg | UC Participants: Dose Escalated to Vedolizumab 300 mg | CD Participants: Dose Escalated to Vedolizumab 300 mg |
|---|---|---|---|---|---|---|---|---|---|---|
| Change at Week 24 | — | 2.5 ± 0.71 | 3.0 ± 2.83 | 6.0 ± NA | 1.0 ± 2.83 | 0.7 ± 1.80 | 2.0 ± NA | 1.0 ± 4.90 | -0.6 ± 2.24 | -2.0 ± 2.65 |
| Change at Week 48 | — | 2.0 ± NA | 0.0 ± NA | 6.0 ± NA | -1.0 ± 2.83 | -1.3 ± 3.27 | 4.0 ± NA | 3.4 ± 3.44 | -0.2 ± 2.91 | -1.3 ± 3.21 |
| Change at Week 72 | — | 2.0 ± NA | 3.0 ± NA | 6.0 ± NA | 0.5 ± 0.71 | -0.4 ± 1.34 | 5.0 ± NA | 5.0 ± 4.58 | -0.1 ± 2.53 | 0.7 ± 1.53 |
| Change at Week 96 | — | 2.0 ± NA | 4.0 ± NA | 2.0 ± NA | 1.5 ± 2.12 | -0.6 ± 2.61 | 4.0 ± NA | 2.7 ± 6.35 | 0.7 ± 1.50 | 0.0 ± 1.41 |
| Change at Week 120 | — | 1.0 ± NA | 6.0 ± NA | 7.0 ± NA | 0.5 ± 2.12 | 0.6 ± 2.97 | 3.0 ± NA | -2.7 ± 1.53 | -1.6 ± 3.54 | 1.0 ± 2.83 |
| Change at Week 144 | — | 3.0 ± NA | 6.0 ± NA | 0.0 ± NA | 1.0 ± 2.83 | 1.3 ± 3.50 | 2.0 ± NA | -1.0 ± 3.00 | -1.0 ± 2.90 | 1.5 ± 0.71 |
| Change at Week 168 | — | 3.0 ± NA | 6.0 ± NA | 10.0 ± NA | 1.0 ± 1.41 | 0.3 ± 2.50 | 1.0 ± NA | 2.3 ± 3.06 | -0.7 ± 3.88 | 1.0 ± 0.00 |
| Change at Week 192 | — | 2.0 ± NA | — | 7.0 ± NA | 3.0 ± NA | 2.0 ± 3.65 | 2.0 ± NA | 2.3 ± 3.51 | -1.3 ± 5.16 | -4.5 ± 7.78 |
| Change at Week 216 | — | 1.0 ± NA | — | 6.0 ± NA | 1.5 ± 2.12 | 1.5 ± 2.65 | 0.0 ± NA | 1.5 ± 3.54 | -1.7 ± 5.75 | 0.0 ± 2.83 |
| Change at Week 240 | — | 3.0 ± NA | — | — | 1.5 ± 2.12 | 3.0 ± 4.24 | 4.0 ± NA | 0.0 ± 4.24 | -0.3 ± 4.80 | 0.0 ± 2.83 |
| Change at Week 264 | — | 2.0 ± NA | — | — | 0.5 ± 3.54 | 1.5 ± 3.54 | — | 3.0 ± NA | 1.7 ± 3.79 | 0.5 ± 2.12 |
| Change at Week 288 | — | — | — | — | -4.0 ± NA | 5.0 ± 1.41 | — | 5.0 ± NA | 2.0 ± 5.66 | 1.0 ± NA |
| Change at Week 312 | — | — | — | — | -3.0 ± NA | 0.0 ± NA | — | 4.0 ± NA | 4.0 ± 4.24 | 0.0 ± NA |
The IMPACT-III questionnaire was a self-reported measure with 35 closed questions encompassing 6 domains. The systemic symptoms domain consisted of 3 items. Each item was scored using a 5-point Likert scale ranging from 1 to 5. The systemic symptoms domain score ranged from 3 to 15, with higher scores suggesting a better quality of life.
| score on a scale | UC Participants (< 30 kg): Vedolizumab 100 mg | UC Participants (< 30 kg): Vedolizumab 200 mg | CD Participants (< 30 kg): Vedolizumab 100 mg | CD Participants (< 30 kg): Vedolizumab 200 mg | UC Participants (>=30 kg): Vedolizumab 150 mg | UC Participants (>=30 kg): Vedolizumab 300 mg | CD Participants (>=30 kg): Vedolizumab 150 mg | CD Participants (>=30 kg): Vedolizumab 300 mg | UC Participants: Dose Escalated to Vedolizumab 300 mg | CD Participants: Dose Escalated to Vedolizumab 300 mg |
|---|---|---|---|---|---|---|---|---|---|---|
| Change at Week 24 | — | 2.0 ± 1.41 | 3.0 ± 5.66 | 3.0 ± NA | 0.0 ± 2.83 | -1.1 ± 1.86 | 0.0 ± NA | 0.9 ± 1.77 | -0.3 ± 1.41 | -0.3 ± 1.53 |
| Change at Week 48 | — | 1.0 ± NA | 2.0 ± NA | 4.0 ± NA | -1.0 ± 1.41 | -0.5 ± 1.38 | 3.0 ± NA | 1.4 ± 2.41 | -0.3 ± 1.41 | 0.3 ± 0.58 |
| Change at Week 72 | — | 0.0 ± NA | 6.0 ± NA | 1.0 ± NA | -0.5 ± 4.95 | -1.8 ± 3.27 | 2.0 ± NA | 2.3 ± 3.21 | -0.4 ± 0.92 | 0.7 ± 1.15 |
| Change at Week 96 | — | 3.0 ± NA | 6.0 ± NA | -1.0 ± NA | 0.5 ± 3.54 | -0.4 ± 2.07 | 3.0 ± NA | 1.3 ± 4.16 | -0.4 ± 2.07 | -0.5 ± 0.71 |
| Change at Week 120 | — | 0.0 ± NA | 7.0 ± NA | 1.0 ± NA | 0.0 ± 1.41 | -0.6 ± 1.14 | 0.0 ± NA | 1.0 ± 1.73 | -0.8 ± 3.20 | -1.5 ± 2.12 |
| Change at Week 144 | — | 1.0 ± NA | 6.0 ± NA | 1.0 ± NA | 1.0 ± 2.83 | 0.8 ± 2.99 | 3.0 ± NA | 0.7 ± 0.58 | 0.0 ± 1.55 | -0.5 ± 0.71 |
| Change at Week 168 | — | 1.0 ± NA | 6.0 ± NA | 3.0 ± NA | -2.5 ± 4.95 | 0.0 ± 3.37 | -1.0 ± NA | 1.0 ± 1.73 | -1.2 ± 3.87 | -2.0 ± 0.00 |
| Change at Week 192 | — | 2.0 ± NA | — | 3.0 ± NA | 3.0 ± NA | 0.0 ± 2.16 | 1.0 ± NA | 1.0 ± 1.00 | -0.2 ± 2.64 | -3.5 ± 4.95 |
| Change at Week 216 | — | 0.0 ± NA | — | 3.0 ± NA | 0.5 ± 2.12 | -1.3 ± 2.75 | 1.0 ± NA | 0.0 ± 2.83 | 0.2 ± 2.14 | -1.0 ± 1.41 |
| Change at Week 240 | — | 2.0 ± NA | — | — | 0.5 ± 2.12 | 0.0 ± 0.00 | 2.0 ± NA | 2.0 ± 1.41 | -0.5 ± 2.07 | -1.5 ± 2.12 |
| Change at Week 264 | — | 0.00 ± NA | — | — | -0.5 ± 0.71 | 0.5 ± 3.54 | — | 1.0 ± NA | -1.3 ± 2.52 | 0.0 ± 0.00 |
| Change at Week 288 | — | — | — | — | -4.0 ± NA | 0.5 ± 0.71 | — | 1.0 ± NA | 0.0 ± 0.00 | 0.0 ± NA |
| Change at Week 312 | — | — | — | — | -4.0 ± NA | -5.0 ± NA | — | 1.0 ± NA | 0.0 ± 0.00 | 0.0 ± NA |
The IMPACT-III questionnaire was a self-reported measure with 35 closed questions encompassing 6 domains. The social functioning domain consisted of 12 items. Each item was scored using a 5-point Likert scale ranging from 1 to 5. The social functioning domain score ranged from 12 to 60, with higher scores suggesting a better quality of life.
| score on a scale | UC Participants (< 30 kg): Vedolizumab 100 mg | UC Participants (< 30 kg): Vedolizumab 200 mg | CD Participants (< 30 kg): Vedolizumab 100 mg | CD Participants (< 30 kg): Vedolizumab 200 mg | UC Participants (>=30 kg): Vedolizumab 150 mg | UC Participants (>=30 kg): Vedolizumab 300 mg | CD Participants (>=30 kg): Vedolizumab 150 mg | CD Participants (>=30 kg): Vedolizumab 300 mg | UC Participants: Dose Escalated to Vedolizumab 300 mg | CD Participants: Dose Escalated to Vedolizumab 300 mg |
|---|---|---|---|---|---|---|---|---|---|---|
| Change at Week 24 | — | 0.0 ± 1.41 | 3.0 ± 7.07 | 0.0 ± NA | 3.5 ± 3.54 | -1.7 ± 2.75 | 1.0 ± NA | 1.1 ± 3.98 | -1.1 ± 3.22 | -3.3 ± 1.53 |
| Change at Week 48 | — | 2.0 ± NA | 3.0 ± NA | 1.0 ± NA | 1.0 ± 2.83 | -0.8 ± 2.71 | 3.0 ± NA | 3.4 ± 7.02 | 0.1 ± 4.57 | -0.7 ± 4.04 |
| Change at Week 72 | — | -4.0 ± NA | 2.0 ± NA | -2.0 ± NA | 6.0 ± 4.24 | -0.2 ± 2.28 | 6.0 ± NA | 5.7 ± 10.60 | 0.3 ± 2.38 | -1.0 ± 3.61 |
| Change at Week 96 | — | 2.0 ± NA | 6.0 ± NA | -4.0 ± NA | 4.5 ± 3.54 | -1.8 ± 3.70 | 6.0 ± NA | 7.7 ± 11.72 | 1.0 ± 3.65 | -2.0 ± 7.07 |
| Change at Week 120 | — | -2.0 ± NA | 4.0 ± NA | 7.0 ± NA | 4.0 ± 2.83 | 0.6 ± 1.14 | 4.0 ± NA | 0.0 ± 1.73 | -0.1 ± 1.77 | -2.0 ± 5.66 |
| Change at Week 144 | — | 0.0 ± NA | 9.0 ± NA | -8.0 ± NA | 5.0 ± 4.24 | -0.8 ± 3.20 | -5.0 ± NA | 0.7 ± 2.31 | -0.5 ± 2.17 | -1.0 ± 4.24 |
| Change at Week 168 | — | 0.0 ± NA | 3.0 ± NA | 13.0 ± NA | 4.5 ± 6.36 | -0.5 ± 3.70 | 0.0 ± NA | 2.3 ± 6.51 | 0.2 ± 3.76 | -2.5 ± 3.54 |
| Change at Week 192 | — | -2.0 ± NA | — | 6.0 ± NA | 9.0 ± NA | -0.5 ± 5.45 | 2.0 ± NA | -0.7 ± 3.21 | -0.3 ± 0.82 | -3.0 ± 2.83 |
| Change at Week 216 | — | -1.0 ± NA | — | 2.0 ± NA | 4.0 ± 2.83 | 0.3 ± 4.03 | 1.0 ± NA | -2.0 ± 0.00 | -1.3 ± 3.98 | -2.0 ± 1.41 |
| Change at Week 240 | — | -2.0 ± NA | — | — | 3.5 ± 9.19 | 0.0 ± 2.83 | 6.0 ± NA | -1.0 ± 0.00 | -1.8 ± 3.76 | -3.5 ± 3.54 |
| Change at Week 264 | — | 2.0 ± NA | — | — | 4.5 ± 4.95 | 1.5 ± 4.95 | — | 2.0 ± NA | 0.3 ± 3.21 | -3.0 ± 5.66 |
| Change at Week 288 | — | — | — | — | 1.0 ± NA | 3.5 ± 3.54 | — | -1.0 ± NA | 0.0 ± 0.00 | -2.0 ± NA |
| Change at Week 312 | — | — | — | — | 2.0 ± NA | -2.0 ± NA | — | 1.0 ± NA | -1.5 ± 2.12 | -1.0 ± NA |
The IMPACT-III questionnaire was a self-reported measure with 35 closed questions encompassing 6 domains. The body image domain consisted of 3 items. Each item was scored using a 5-point Likert scale ranging from 1 to 5. The body image domain score ranged from 3 to 15, with higher scores suggesting a better quality of life.
| score on a scale | UC Participants (< 30 kg): Vedolizumab 100 mg | UC Participants (< 30 kg): Vedolizumab 200 mg | CD Participants (< 30 kg): Vedolizumab 100 mg | CD Participants (< 30 kg): Vedolizumab 200 mg | UC Participants (>=30 kg): Vedolizumab 150 mg | UC Participants (>=30 kg): Vedolizumab 300 mg | CD Participants (>=30 kg): Vedolizumab 150 mg | CD Participants (>=30 kg): Vedolizumab 300 mg | UC Participants: Dose Escalated to Vedolizumab 300 mg | CD Participants: Dose Escalated to Vedolizumab 300 mg |
|---|---|---|---|---|---|---|---|---|---|---|
| Change at Week 24 | — | -2.5 ± 0.71 | 0.5 ± 0.71 | -2.0 ± NA | 1.5 ± 2.12 | -0.3 ± 0.49 | -1.0 ± NA | -0.1 ± 1.57 | 0.6 ± 1.81 | -1.7 ± 0.58 |
| Change at Week 48 | — | -1.0 ± NA | -1.0 ± NA | -2.0 ± NA | 1.5 ± 3.54 | -0.2 ± 1.17 | 0.0 ± NA | -0.4 ± 2.61 | 0.1 ± 0.78 | 0.0 ± 2.00 |
| Change at Week 72 | — | -3.0 ± NA | 0.0 ± NA | -1.0 ± NA | 2.0 ± 2.83 | 0.8 ± 2.17 | -3.0 ± NA | 0.7 ± 1.15 | -0.6 ± 1.30 | 3.3 ± 1.15 |
| Change at Week 96 | — | -2.0 ± NA | 0.0 ± NA | 0.0 ± NA | 1.5 ± 2.12 | 1.0 ± 2.00 | -1.0 ± NA | 1.7 ± 6.66 | -0.3 ± 1.38 | 1.0 ± 1.41 |
| Change at Week 120 | — | -5.0 ± NA | 3.0 ± NA | 1.0 ± NA | 1.5 ± 2.12 | 0.8 ± 1.64 | -4.0 ± NA | 0.3 ± 3.79 | -0.5 ± 2.20 | 1.0 ± 0.00 |
| Change at Week 144 | — | -5.0 ± NA | 4.0 ± NA | -6.0 ± NA | 1.0 ± 1.41 | 0.5 ± 1.00 | -5.0 ± NA | 0.7 ± 2.08 | -0.8 ± 1.94 | 1.0 ± 0.00 |
| Change at Week 168 | — | -3.0 ± NA | 3.0 ± NA | 0.0 ± NA | 1.5 ± 2.12 | 0.5 ± 1.00 | -6.0 ± NA | 1.3 ± 2.89 | 0.3 ± 1.75 | 0.5 ± 0.71 |
| Change at Week 192 | — | -4.0 ± NA | — | 0.0 ± NA | 0.0 ± NA | 1.3 ± 1.50 | -4.0 ± NA | 1.7 ± 2.52 | -0.3 ± 2.42 | 0.0 ± 0.00 |
| Change at Week 216 | — | 0.0 ± NA | — | -1.0 ± NA | 2.0 ± 1.41 | 0.8 ± 0.96 | -4.0 ± NA | 0.0 ± 4.24 | 0.3 ± 2.16 | 2.0 ± 1.41 |
| Change at Week 240 | — | -3.0 ± NA | — | — | 2.00 ± 0.00 | 0.5 ± 0.71 | -4.0 ± NA | -2.0 ± 2.83 | 0.3 ± 2.16 | 1.0 ± 1.41 |
| Change at Week 264 | — | -3.0 ± NA | — | — | 1.0 ± 1.41 | 0.0 ± 1.41 | — | -3.0 ± NA | -0.3 ± 2.52 | 2.5 ± 0.71 |
| Change at Week 288 | — | — | — | — | 2.0 ± NA | 1.5 ± 0.71 | — | -3.0 ± NA | 0.0 ± 2.83 | 2.0 ± NA |
| Change at Week 312 | — | — | — | — | 3.0 ± NA | 0.0 ± NA | — | -1.0 ± NA | -1.0 ± 2.83 | 0.0 ± NA |
The IMPACT-III questionnaire was a self-reported measure with 35 closed questions encompassing 6 domains. The treatment/interventions domain consisted of 3 items. Each item was scored using a 5-point Likert scale ranging from 1 to 5. The treatment/interventions domain score ranged from 3 to 15, with higher scores suggesting a better quality of life.
| score on a scale | UC Participants (< 30 kg): Vedolizumab 100 mg | UC Participants (< 30 kg): Vedolizumab 200 mg | CD Participants (< 30 kg): Vedolizumab 100 mg | CD Participants (< 30 kg): Vedolizumab 200 mg | UC Participants (>=30 kg): Vedolizumab 150 mg | UC Participants (>=30 kg): Vedolizumab 300 mg | CD Participants (>=30 kg): Vedolizumab 150 mg | CD Participants (>=30 kg): Vedolizumab 300 mg | UC Participants: Dose Escalated to Vedolizumab 300 mg | CD Participants: Dose Escalated to Vedolizumab 300 mg |
|---|---|---|---|---|---|---|---|---|---|---|
| Change at Week 24 | — | -1.0 ± 1.41 | 2.0 ± 1.41 | 0.0 ± NA | 1.0 ± 2.83 | 0.1 ± 0.90 | 1.0 ± NA | -1.3 ± 1.80 | -0.3 ± 1.12 | 1.0 ± 1.00 |
| Change at Week 48 | — | 1.0 ± NA | 3.0 ± NA | 3.0 ± NA | 0.5 ± 0.71 | -0.7 ± 1.21 | 0.0 ± NA | 0.4 ± 2.19 | -0.1 ± 0.78 | 0.7 ± 1.53 |
| Change at Week 72 | — | 0.0 ± NA | 0.0 ± NA | 5.0 ± NA | -0.5 ± 2.12 | 0.0 ± 1.22 | 0.0 ± NA | 0.7 ± 2.31 | -0.1 ± 1.36 | 1.0 ± 1.00 |
| Change at Week 96 | — | -1.0 ± NA | 2.0 ± NA | 3.0 ± NA | 1.0 ± 1.41 | -0.2 ± 1.79 | 1.0 ± NA | 0.0 ± 3.46 | 0.3 ± 1.50 | 0.0 ± 0.00 |
| Change at Week 120 | — | -1.0 ± NA | 1.0 ± NA | 6.0 ± NA | 0.0 ± 0.00 | 0.0 ± 1.22 | -1.0 ± NA | -3.3 ± 1.15 | -0.4 ± 2.07 | 0.0 ± 0.00 |
| Change at Week 144 | — | -1.0 ± NA | 3.0 ± NA | 2.0 ± NA | 0.5 ± 0.71 | 0.8 ± 1.71 | -1.0 ± NA | -1.3 ± 3.06 | -0.1 ± 2.19 | 0.5 ± 0.71 |
| Change at Week 168 | — | 0.0 ± NA | 2.0 ± NA | 5.0 ± NA | 0.5 ± 0.71 | 0.3 ± 1.71 | 0.0 ± NA | -0.3 ± 3.21 | -0.7 ± 2.25 | 1.0 ± 0.00 |
| Change at Week 192 | — | -2.0 ± NA | — | 4.0 ± NA | 0.0 ± NA | 1.0 ± 0.82 | -1.0 ± NA | 0.3 ± 1.53 | -1.2 ± 2.48 | 0.5 ± 0.71 |
| Change at Week 216 | — | -1.0 ± NA | — | 4.0 ± NA | 1.5 ± 2.12 | 1.5 ± 1.91 | 1.0 ± NA | -0.5 ± 0.71 | -0.7 ± 3.08 | 0.5 ± 0.71 |
| Change at Week 240 | — | -1.0 ± NA | — | — | 0.5 ± 0.71 | 1.0 ± 1.41 | 3.0 ± NA | 0.0 ± 1.41 | -0.2 ± 2.64 | 0.5 ± 0.71 |
| Change at Week 264 | — | -2.0 ± NA | — | — | 0.5 ± 0.71 | 1.5 ± 2.12 | — | 2.0 ± NA | 0.7 ± 0.58 | 1.0 ± 0.00 |
| Change at Week 288 | — | — | — | — | 0.0 ± NA | 1.5 ± 0.71 | — | -1.0 ± NA | 1.5 ± 2.12 | 2.0 ± NA |
| Change at Week 312 | — | — | — | — | 0.0 ± NA | 0.0 ± NA | — | 2.0 ± NA | 1.0 ± 1.41 | 2.0 ± NA |
The IMPACT-III questionnaire was a self-reported measure with 35 closed questions encompassing 6 domains. The emotional functioning domain consisted of 7 items. Each item was scored using a 5-point Likert scale ranging from 1 to 5. The emotional functioning domain score ranged from 7 to 35, with higher scores suggesting a better quality of life.
| score on a scale | UC Participants (< 30 kg): Vedolizumab 100 mg | UC Participants (< 30 kg): Vedolizumab 200 mg | CD Participants (< 30 kg): Vedolizumab 100 mg | CD Participants (< 30 kg): Vedolizumab 200 mg | UC Participants (>=30 kg): Vedolizumab 150 mg | UC Participants (>=30 kg): Vedolizumab 300 mg | CD Participants (>=30 kg): Vedolizumab 150 mg | CD Participants (>=30 kg): Vedolizumab 300 mg | UC Participants: Dose Escalated to Vedolizumab 300 mg | CD Participants: Dose Escalated to Vedolizumab 300 mg |
|---|---|---|---|---|---|---|---|---|---|---|
| Change at Week 24 | — | 0.0 ± 0.00 | 1.5 ± 2.12 | 3.0 ± NA | 2.0 ± 4.24 | -2.0 ± 2.89 | 5.0 ± NA | 1.1 ± 2.79 | -1.1 ± 3.02 | 0.0 ± 1.73 |
| Change at Week 48 | — | 1.0 ± NA | 1.0 ± NA | 7.0 ± NA | 1.5 ± 2.12 | -2.5 ± 6.35 | 6.0 ± NA | 2.8 ± 4.66 | -0.8 ± 4.09 | -0.3 ± 1.53 |
| Change at Week 72 | — | 0.0 ± NA | 0.0 ± NA | 3.0 ± NA | 3.0 ± 1.41 | 0.4 ± 4.04 | 7.0 ± NA | 5.3 ± 4.93 | 0.6 ± 3.20 | -0.7 ± 1.53 |
| Change at Week 96 | — | -2.0 ± NA | 0.0 ± NA | 8.0 ± NA | 4.0 ± 4.24 | -1.4 ± 5.68 | 9.0 ± NA | 4.0 ± 7.55 | 0.9 ± 3.53 | 0.0 ± 0.00 |
| Change at Week 120 | — | -1.0 ± NA | 3.0 ± NA | 10.0 ± NA | 5.0 ± 1.41 | 0.2 ± 3.27 | 6.0 ± NA | 2.0 ± 2.00 | -1.9 ± 5.00 | -2.0 ± 1.41 |
| Change at Week 144 | — | -2.0 ± NA | 3.0 ± NA | 1.0 ± NA | 5.5 ± 2.12 | -0.8 ± 5.12 | 0.0 ± NA | 1.0 ± 3.61 | -2.7 ± 3.78 | -2.5 ± 4.95 |
| Change at Week 168 | — | 0.0 ± NA | 1.0 ± NA | 11.0 ± NA | 2.5 ± 0.71 | -0.3 ± 5.80 | 0.0 ± NA | 2.0 ± 2.65 | -2.3 ± 5.79 | -1.0 ± 0.00 |
| Change at Week 192 | — | -4.0 ± NA | — | 9.0 ± NA | 6.0 ± NA | 1.0 ± 6.16 | 7.0 ± NA | 3.7 ± 2.52 | -2.5 ± 6.25 | -2.0 ± 2.83 |
| Change at Week 216 | — | -4.0 ± NA | — | 7.0 ± NA | 5.0 ± 2.83 | 1.0 ± 5.35 | 5.0 ± NA | 3.0 ± 2.83 | -2.5 ± 7.31 | 0.0 ± 0.00 |
| Change at Week 240 | — | 0.0 ± NA | — | — | 4.5 ± 2.12 | 0.5 ± 0.71 | 4.0 ± NA | 1.0 ± 4.24 | -3.3 ± 7.45 | -1.0 ± 1.41 |
| Change at Week 264 | — | -2.0 ± NA | — | — | 3.5 ± 2.12 | 3.5 ± 4.95 | — | 4.0 ± NA | 1.0 ± 3.00 | 0.0 ± 0.00 |
| Change at Week 288 | — | — | — | — | 3.0 ± NA | 5.0 ± 5.66 | — | 4.0 ± NA | 3.0 ± 2.83 | 0.0 ± NA |
| Change at Week 312 | — | — | — | — | 4.0 ± NA | 0.0 ± NA | — | 5.0 ± NA | 2.0 ± 2.83 | 0.0 ± NA |
Height velocity (centimeter per year \[cm/year\]) was calculated as the change in height divided by the duration \[time between the two height measures\].
| cm/year | UC Participants (< 30 kg): Vedolizumab 100 mg | UC Participants (< 30 kg): Vedolizumab 200 mg | CD Participants (< 30 kg): Vedolizumab 100 mg | CD Participants (< 30 kg): Vedolizumab 200 mg | UC Participants (>=30 kg): Vedolizumab 150 mg | UC Participants (>=30 kg): Vedolizumab 300 mg | CD Participants (>=30 kg): Vedolizumab 150 mg | CD Participants (>=30 kg): Vedolizumab 300 mg |
|---|---|---|---|---|---|---|---|---|
| At Week 48 | 0.02 ± 0.006 | 0.02 ± 0.007 | 0.02 ± 0.005 | 0.01 ± 0.003 | 0.01 ± 0.008 | 0.01 ± 0.010 | 0.01 ± 0.007 | 0.01 ± 0.008 |
| At Week 96 | 0.02 ± 0.003 | 0.02 ± 0.006 | 0.02 ± 0.004 | 0.02 ± 0.004 | 0.01 ± 0.007 | 0.01 ± 0.011 | 0.01 ± 0.007 | 0.01 ± 0.007 |
| At Week 144 | 0.02 ± 0.003 | 0.02 ± 0.004 | 0.02 ± 0.002 | 0.02 ± 0.006 | 0.01 ± 0.008 | 0.01 ± 0.011 | 0.00 ± 0.001 | 0.01 ± 0.008 |
| At Week 192 | 0.02 ± 0.003 | 0.01 ± 0.004 | 0.02 ± 0.001 | 0.02 ± 0.005 | 0.01 ± 0.008 | 0.01 ± 0.010 | 0.00 ± 0.001 | 0.01 ± 0.007 |
| At Week 240 | 0.02 ± 0.003 | 0.02 ± 0.006 | 0.02 ± 0.001 | 0.02 ± NA | 0.01 ± 0.007 | 0.01 ± 0.010 | 0.00 ± 0.001 | 0.01 ± 0.007 |
| At Week 288 | — | 0.02 ± 0.001 | 0.02 ± NA | — | 0.01 ± 0.004 | 0.01 ± 0.008 | 0.00 ± NA | 0.01 ± NA |
| At Week 336 | — | — | — | — | 0.01 ± NA | — | — | — |
Change from baseline in height was reported.
| cm | UC Participants (< 30 kg): Vedolizumab 100 mg | UC Participants (< 30 kg): Vedolizumab 200 mg | CD Participants (< 30 kg): Vedolizumab 100 mg | CD Participants (< 30 kg): Vedolizumab 200 mg | UC Participants (>=30 kg): Vedolizumab 150 mg | UC Participants (>=30 kg): Vedolizumab 300 mg | CD Participants (>=30 kg): Vedolizumab 150 mg | CD Participants (>=30 kg): Vedolizumab 300 mg |
|---|---|---|---|---|---|---|---|---|
| Change at Week 48 | 5.80 ± 1.878 | 6.44 ± 2.289 | 8.30 ± 1.649 | 5.08 ± 1.179 | 4.64 ± 2.741 | 3.22 ± 3.382 | 4.48 ± 2.450 | 2.83 ± 2.658 |
| Change at Week 96 | 12.80 ± 2.339 | 11.83 ± 4.209 | 15.15 ± 2.954 | 12.28 ± 2.520 | 8.78 ± 4.687 | 8.18 ± 7.473 | 5.17 ± 4.726 | 4.77 ± 4.866 |
| Change at Week 144 | 20.65 ± 3.323 | 15.50 ± 3.888 | 20.23 ± 2.452 | 20.03 ± 6.473 | 12.46 ± 7.791 | 9.73 ± 10.675 | 4.15 ± 0.919 | 7.85 ± 7.861 |
| Change at Week 192 | 25.90 ± 3.394 | 19.84 ± 6.006 | 24.02 ± 1.574 | 25.87 ± 6.358 | 14.26 ± 10.938 | 12.53 ± 14.093 | 4.15 ± 0.919 | 9.48 ± 9.566 |
| Change at Week 240 | 32.00 ± 4.243 | 26.48 ± 9.710 | 29.00 ± 2.345 | 26.00 ± NA | 15.57 ± 12.529 | 18.73 ± 16.839 | 4.25 ± 1.061 | 12.70 ± 11.801 |
| Change at Week 288 | — | 39.75 ± 1.768 | 33.00 ± NA | — | 21.60 ± 9.002 | 25.50 ± 15.415 | 3.50 ± NA | 25.80 ± NA |
| Change at Week 336 | — | — | — | — | 29.00 ± NA | — | — | — |
Change from baseline in weight was reported.
| kg | UC Participants (< 30 kg): Vedolizumab 100 mg | UC Participants (< 30 kg): Vedolizumab 200 mg | CD Participants (< 30 kg): Vedolizumab 100 mg | CD Participants (< 30 kg): Vedolizumab 200 mg | UC Participants (>=30 kg): Vedolizumab 150 mg | UC Participants (>=30 kg): Vedolizumab 300 mg | CD Participants (>=30 kg): Vedolizumab 150 mg | CD Participants (>=30 kg): Vedolizumab 300 mg |
|---|---|---|---|---|---|---|---|---|
| Change at Week 24 | 1.40 ± 1.259 | 2.44 ± 1.813 | 2.31 ± 1.519 | 0.88 ± 0.435 | 2.04 ± 4.477 | -1.10 ± 4.196 | 2.00 ± 7.579 | 1.73 ± 4.797 |
| Change at Week 48 | 3.03 ± 1.917 | 5.93 ± 4.009 | 4.95 ± 2.536 | 2.45 ± 1.063 | 5.78 ± 6.641 | 1.27 ± 7.481 | 7.70 ± 5.227 | 3.75 ± 5.496 |
| Change at Week 72 | 4.30 ± 2.276 | 8.44 ± 4.873 | 7.00 ± 4.782 | 3.58 ± 1.242 | 8.27 ± 8.209 | 4.66 ± 11.602 | 12.63 ± 7.228 | 5.48 ± 5.775 |
| Change at Week 96 | 5.90 ± 3.119 | 10.03 ± 5.347 | 8.80 ± 4.964 | 5.73 ± 1.999 | 11.61 ± 10.137 | 5.88 ± 13.031 | 10.57 ± 2.663 | 6.68 ± 11.022 |
| Change at Week 120 | 9.45 ± 5.728 | 12.11 ± 5.128 | 10.42 ± 4.548 | 7.70 ± 2.451 | 12.14 ± 10.812 | 9.58 ± 14.815 | 9.35 ± 3.465 | 7.63 ± 11.213 |
| Change at Week 144 | 10.65 ± 5.445 | 12.72 ± 3.916 | 12.73 ± 4.809 | 10.53 ± 4.554 | 14.01 ± 10.775 | 11.30 ± 19.539 | 10.30 ± 2.970 | 9.70 ± 16.931 |
| Change at Week 168 | 12.20 ± 2.546 | 12.64 ± 4.659 | 13.62 ± 5.493 | 12.17 ± 4.819 | 14.11 ± 10.805 | 11.93 ± 19.493 | 10.55 ± 4.172 | 10.60 ± 18.655 |
| Change at Week 192 | 15.25 ± 4.596 | 12.54 ± 3.153 | 15.20 ± 6.001 | 13.53 ± 5.181 | 16.01 ± 11.200 | 13.75 ± 23.604 | 11.70 ± 0.990 | 9.65 ± 18.013 |
| Change at Week 216 | 16.50 ± 5.515 | 16.33 ± 1.875 | 15.98 ± 4.270 | 12.45 ± 5.869 | 17.47 ± 10.019 | 15.23 ± 26.238 | 11.40 ± 1.980 | 15.53 ± 19.570 |
| Change at Week 240 | 18.15 ± 6.435 | 18.42 ± 1.952 | 19.20 ± 3.876 | 11.30 ± NA | 19.74 ± 11.097 | 27.90 ± 26.121 | 12.15 ± 0.919 | 17.33 ± 20.702 |
| Change at Week 264 | — | 22.77 ± 0.289 | 21.27 ± 2.810 | 12.70 ± NA | 18.24 ± 13.130 | 35.67 ± 34.619 | 12.00 ± 0.707 | 44.60 ± NA |
| Change at Week 288 | — | 26.30 ± 0.707 | 25.60 ± NA | — | 24.77 ± 10.383 | 60.55 ± 24.112 | 13.00 ± NA | 49.60 ± NA |
| Change at Week 312 | — | 30.80 ± NA | — | — | 27.40 ± 10.180 | 75.60 ± NA | 13.00 ± NA | 63.30 ± NA |
| Change at Week 336 | — | — | — | — | 17.00 ± NA | — | — | — |
BMI was calculated as Weight (in kilograms)/height (in meters square).
| kg/m^2 | UC Participants (< 30 kg): Vedolizumab 100 mg | UC Participants (< 30 kg): Vedolizumab 200 mg | CD Participants (< 30 kg): Vedolizumab 100 mg | CD Participants (< 30 kg): Vedolizumab 200 mg | UC Participants (>=30 kg): Vedolizumab 150 mg | UC Participants (>=30 kg): Vedolizumab 300 mg | CD Participants (>=30 kg): Vedolizumab 150 mg | CD Participants (>=30 kg): Vedolizumab 300 mg |
|---|---|---|---|---|---|---|---|---|
| Change at Week 24 | 0.22 ± 0.850 | 0.31 ± 0.909 | 0.26 ± 0.556 | -0.10 ± 0.535 | 0.31 ± 1.547 | -0.60 ± 1.238 | 0.40 ± 2.787 | 0.35 ± 2.076 |
| Change at Week 48 | 0.57 ± 1.115 | 1.29 ± 1.515 | 0.83 ± 0.802 | 0.38 ± 0.967 | 1.28 ± 2.644 | -0.17 ± 2.460 | 1.95 ± 2.278 | 0.93 ± 1.894 |
| Change at Week 72 | 0.52 ± 0.737 | 1.80 ± 1.455 | 0.93 ± 1.384 | 0.18 ± 0.862 | 1.66 ± 3.011 | 0.52 ± 3.552 | 3.43 ± 2.392 | 1.12 ± 1.899 |
| Change at Week 96 | 0.80 ± 1.127 | 1.89 ± 1.823 | 0.98 ± 1.089 | 0.48 ± 0.780 | 2.53 ± 4.023 | 0.50 ± 3.742 | 2.40 ± 0.436 | 1.60 ± 3.123 |
| Change at Week 120 | 1.80 ± 2.263 | 2.30 ± 1.354 | 1.30 ± 0.951 | 0.63 ± 1.141 | 2.56 ± 4.169 | 1.44 ± 4.106 | 2.30 ± 0.990 | 1.33 ± 2.784 |
| Change at Week 144 | 1.45 ± 1.909 | 2.42 ± 0.889 | 1.77 ± 1.176 | 1.23 ± 1.704 | 2.69 ± 4.110 | 2.10 ± 5.314 | 2.50 ± 0.990 | 1.88 ± 4.522 |
| Change at Week 168 | 1.65 ± 0.071 | 2.22 ± 1.582 | 1.85 ± 1.408 | 1.37 ± 1.762 | 2.37 ± 4.514 | 1.87 ± 6.058 | 2.60 ± 1.414 | 1.85 ± 4.689 |
| Change at Week 192 | 2.75 ± 1.061 | 1.58 ± 1.470 | 2.20 ± 1.661 | 1.33 ± 1.457 | 2.81 ± 4.273 | 2.25 ± 6.186 | 2.95 ± 0.354 | 1.30 ± 4.220 |
| Change at Week 216 | 2.50 ± 1.131 | 2.15 ± 1.834 | 2.16 ± 1.212 | 0.15 ± 0.212 | 3.14 ± 4.011 | 2.50 ± 6.862 | 2.85 ± 0.636 | 2.50 ± 4.151 |
| Change at Week 240 | 2.60 ± 1.556 | 2.55 ± 2.275 | 3.15 ± 1.266 | 1.60 ± NA | 3.80 ± 4.548 | 6.00 ± 7.428 | 3.10 ± 0.283 | 3.17 ± 4.499 |
| Change at Week 264 | — | 2.47 ± 1.447 | 3.70 ± 1.015 | 1.80 ± NA | 2.70 ± 5.162 | 8.53 ± 10.388 | 3.05 ± 0.212 | 9.40 ± NA |
| Change at Week 288 | — | 3.15 ± 1.909 | 5.00 ± NA | — | 4.87 ± 6.745 | 17.15 ± 14.071 | 3.40 ± NA | 11.30 ± NA |
| Change at Week 312 | — | 5.60 ± NA | — | — | 5.53 ± 6.475 | 22.00 ± NA | 3.40 ± NA | 16.40 ± NA |
| Change at Week 336 | — | — | — | — | 0.00 ± NA | — | — | — |
Tanner Stage Evaluation was a scale used to evaluate growth parameters standardized for age, sex, and pubertal development. Female pubertal development staged by pubic hair development and breast size; male pubertal development staged by size of the genitalia and development of pubic hair. Rated in 5 stages: stage 1 (no development) to 5 (adult-like development in quantity and size). Tanner stage was assessed at or before age 16 years for females or 17 years for males.
| percentage of participants | UC Participants (< 30 kg): Vedolizumab 100 mg | UC Participants (< 30 kg): Vedolizumab 200 mg | CD Participants (< 30 kg): Vedolizumab 100 mg | CD Participants (< 30 kg): Vedolizumab 200 mg | UC Participants (>=30 kg): Vedolizumab 150 mg | UC Participants (>=30 kg): Vedolizumab 300 mg | CD Participants (>=30 kg): Vedolizumab 150 mg | CD Participants (>=30 kg): Vedolizumab 300 mg |
|---|---|---|---|---|---|---|---|---|
| Males | — | — | 100 | — | 100 | 100 | 100 | 100 |
| Females | — | 50 | — | — | 100 | 100 | — | 100 |
Collected over From first dose of study drug up to end of follow up (up to 6.8 years). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| UC Participants (< 30 kg): Vedolizumab 100 mg | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| UC Participants (< 30 kg): Vedolizumab 200 mg | 0/6 (0%) | 1/6 (16.7%) | 5/6 (83.3%) |
| CD Participants (< 30 kg): Vedolizumab 100 mg | 0/5 (0%) | 0/5 (0%) | 5/5 (100%) |
| CD Participants (< 30 kg): Vedolizumab 200 mg | 0/5 (0%) | 4/5 (80%) | 5/5 (100%) |
| UC Participants (>=30 kg): Vedolizumab 150 mg | 0/2 (0%) | 1/2 (50%) | 2/2 (100%) |
| UC Participants (>=30 kg): Vedolizumab 300 mg | 0/7 (0%) | 3/7 (42.9%) | 6/7 (85.7%) |
| CD Participants (>=30 kg): Vedolizumab 150 mg | 0/2 (0%) | 1/2 (50%) | 2/2 (100%) |
| CD Participants (>=30 kg): Vedolizumab 300 mg | 0/10 (0%) | 4/10 (40%) | 10/10 (100%) |
| UC Participants: Dose Escalated to Vedolizumab 300 mg | 0/12 (0%) | 4/12 (33.3%) | 12/12 (100%) |
| CD Participants: Dose Escalated to Vedolizumab 300 mg | 0/6 (0%) | 1/6 (16.7%) | 6/6 (100%) |
| Event | UC Participants (< 30 kg): Vedolizumab 100 mg | UC Participants (< 30 kg): Vedolizumab 200 mg | CD Participants (< 30 kg): Vedolizumab 100 mg | CD Participants (< 30 kg): Vedolizumab 200 mg | UC Participants (>=30 kg): Vedolizumab 150 mg | UC Participants (>=30 kg): Vedolizumab 300 mg | CD Participants (>=30 kg): Vedolizumab 150 mg | CD Participants (>=30 kg): Vedolizumab 300 mg | UC Participants: Dose Escalated to Vedolizumab 300 mg | CD Participants: Dose Escalated to Vedolizumab 300 mg |
|---|---|---|---|---|---|---|---|---|---|---|
| Infectious mononucleosisInfections and infestations | 0/3 | 0/6 | 0/5 | 0/5 | 1/2 | 0/7 | 0/2 | 0/10 | 0/12 | 0/6 |
| Post procedural haemorrhageInjury, poisoning and procedural complications | 0/3 | 0/6 | 0/5 | 0/5 | 0/2 | 0/7 | 1/2 | 0/10 | 0/12 | 0/6 |
| Crohn's diseaseGastrointestinal disorders | 0/3 | 0/6 | 0/5 | 1/5 | 0/2 | 0/7 | 0/2 | 4/10 | 0/12 | 0/6 |
| Clostridium difficile colitisInfections and infestations | 1/3 | 0/6 | 0/5 | 0/5 | 0/2 | 0/7 | 0/2 | 0/10 | 0/12 | 0/6 |
| Colitis ulcerativeGastrointestinal disorders | 1/3 | 0/6 | 0/5 | 1/5 | 0/2 | 2/7 | 0/2 | 0/10 | 1/12 | 0/6 |
| Abdominal painGastrointestinal disorders | 0/3 | 0/6 | 0/5 | 1/5 | 0/2 | 0/7 | 0/2 | 0/10 | 1/12 | 0/6 |
| ColitisGastrointestinal disorders | 0/3 | 0/6 | 0/5 | 1/5 | 0/2 | 0/7 | 0/2 | 0/10 | 0/12 | 0/6 |
| ExostosisMusculoskeletal and connective tissue disorders | 0/3 | 0/6 | 0/5 | 1/5 | 0/2 | 0/7 | 0/2 | 0/10 | 0/12 | 0/6 |
| Rectal haemorrhageGastrointestinal disorders | 0/3 | 0/6 | 0/5 | 1/5 | 0/2 | 0/7 | 0/2 | 0/10 | 0/12 | 0/6 |
| UrticariaSkin and subcutaneous tissue disorders | 0/3 | 0/6 | 0/5 | 1/5 | 0/2 | 0/7 | 0/2 | 0/10 | 0/12 | 0/6 |
| Event | UC Participants (< 30 kg): Vedolizumab 100 mg | UC Participants (< 30 kg): Vedolizumab 200 mg | CD Participants (< 30 kg): Vedolizumab 100 mg | CD Participants (< 30 kg): Vedolizumab 200 mg | UC Participants (>=30 kg): Vedolizumab 150 mg | UC Participants (>=30 kg): Vedolizumab 300 mg | CD Participants (>=30 kg): Vedolizumab 150 mg | CD Participants (>=30 kg): Vedolizumab 300 mg | UC Participants: Dose Escalated to Vedolizumab 300 mg | CD Participants: Dose Escalated to Vedolizumab 300 mg |
|---|---|---|---|---|---|---|---|---|---|---|
| Crohn's diseaseGastrointestinal disorders | 0/3 | 0/6 | 0/5 | 2/5 | 0/2 | 0/7 | 0/2 | 3/10 | 0/12 | 4/6 |
| PyrexiaGeneral disorders | 1/3 | 4/6 | 0/5 | 0/5 | 1/2 | 2/7 | 0/2 | 0/10 | 4/12 | 1/6 |
| Abdominal painGastrointestinal disorders | 0/3 | 1/6 | 0/5 | 1/5 | 1/2 | 1/7 | 0/2 | 3/10 | 4/12 | 1/6 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/3 | 3/6 | 0/5 | 1/5 | 1/2 | 2/7 | 0/2 | 1/10 | 0/12 | 0/6 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/3 | 0/6 | 1/5 | 0/5 | 1/2 | 0/7 | 0/2 | 0/10 | 0/12 | 0/6 |
| Blood iron decreasedInvestigations | 0/3 | 0/6 | 0/5 | 0/5 | 1/2 | 0/7 | 0/2 | 0/10 | 0/12 | 0/6 |
| COVID-19Infections and infestations | 0/3 | 3/6 | 1/5 | 1/5 | 0/2 | 1/7 | 0/2 | 0/10 | 2/12 | 1/6 |
| ChillsGeneral disorders | 0/3 | 0/6 | 0/5 | 0/5 | 1/2 | 0/7 | 0/2 | 0/10 | 0/12 | 0/6 |
| Colitis ulcerativeGastrointestinal disorders | 1/3 | 3/6 | 0/5 | 0/5 | 0/2 | 2/7 | 0/2 | 0/10 | 6/12 | 0/6 |
| DehydrationMetabolism and nutrition disorders | 0/3 | 1/6 | 0/5 | 0/5 | 0/2 | 0/7 | 1/2 | 0/10 | 0/12 | 0/6 |
The enrolled set included all participants enrolled in the study.
| Age, Customized(Participants) | UC Participants (< 30 kg): Vedolizumab 100 mg | UC Participants (< 30 kg): Vedolizumab 200 mg | CD Participants (< 30 kg): Vedolizumab 100 mg | CD Participants (< 30 kg): Vedolizumab 200 mg | UC Participants (>=30 kg): Vedolizumab 150 mg | UC Participants (>=30 kg): Vedolizumab 300 mg | CD Participants (>=30 kg): Vedolizumab 150 mg | CD Participants (>=30 kg): Vedolizumab 300 mg | Total |
|---|---|---|---|---|---|---|---|---|---|
| Children (2-11 years) | 5 | 7 | 5 | 6 | 4 | 2 | 1 | 3 | 33 |
| Adolescents (12-17 years) | 0 | 2 | 2 | 1 | 6 | 5 | 3 | 7 | 26 |
| Sex: Female, Male(Participants) | UC Participants (< 30 kg): Vedolizumab 100 mg | UC Participants (< 30 kg): Vedolizumab 200 mg | CD Participants (< 30 kg): Vedolizumab 100 mg | CD Participants (< 30 kg): Vedolizumab 200 mg | UC Participants (>=30 kg): Vedolizumab 150 mg | UC Participants (>=30 kg): Vedolizumab 300 mg | CD Participants (>=30 kg): Vedolizumab 150 mg | CD Participants (>=30 kg): Vedolizumab 300 mg | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 2 | 3 | 2 | 4 | 4 | 3 | 2 | 5 | 25 |
| Male | 3 | 6 | 5 | 3 | 6 | 4 | 2 | 5 | 34 |
| Ethnicity (NIH/OMB)(Participants) | UC Participants (< 30 kg): Vedolizumab 100 mg | UC Participants (< 30 kg): Vedolizumab 200 mg | CD Participants (< 30 kg): Vedolizumab 100 mg | CD Participants (< 30 kg): Vedolizumab 200 mg | UC Participants (>=30 kg): Vedolizumab 150 mg | UC Participants (>=30 kg): Vedolizumab 300 mg | CD Participants (>=30 kg): Vedolizumab 150 mg | CD Participants (>=30 kg): Vedolizumab 300 mg | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 2 | 2 | 1 | 0 | 1 | 0 | 0 | 6 |
| Not Hispanic or Latino | 5 | 6 | 5 | 5 | 10 | 6 | 4 | 10 | 51 |
| Unknown or Not Reported | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 2 |
| Race (NIH/OMB)(Participants) | UC Participants (< 30 kg): Vedolizumab 100 mg | UC Participants (< 30 kg): Vedolizumab 200 mg | CD Participants (< 30 kg): Vedolizumab 100 mg | CD Participants (< 30 kg): Vedolizumab 200 mg | UC Participants (>=30 kg): Vedolizumab 150 mg | UC Participants (>=30 kg): Vedolizumab 300 mg | CD Participants (>=30 kg): Vedolizumab 150 mg | CD Participants (>=30 kg): Vedolizumab 300 mg | Total |
|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 0 | 0 | 2 | 0 | 0 | 1 | 4 |
| White | 5 | 7 | 5 | 6 | 8 | 5 | 4 | 8 | 48 |
| More than one race | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 2 |
| Unknown or Not Reported | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Jul 2018 to primary completion in Apr 2025, 80 months.
Results were first posted in Mar 2026, 11 months after primary completion.
Of 110 industry-sponsored phase 2 interventional studies under Colitis, Ulcerative, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 35. This study's 80 months is above that.
Counting every sponsor, half of 154 studies reached it within 28 months; a quarter within 22 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vedolizumab